Royce & Associates LP decreased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 36.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 478,465 shares of the biopharmaceutical company’s stock after selling 272,635 shares during the quarter. Royce & Associates LP owned approximately 0.57% of Sangamo Therapeutics worth $7,177,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SGMO. Blair William & Co. IL grew its holdings in Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares during the period. Aperio Group LLC purchased a new stake in Sangamo Therapeutics in the 2nd quarter valued at about $108,000. Principal Financial Group Inc. grew its holdings in Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares during the period. Quantbot Technologies LP purchased a new stake in Sangamo Therapeutics in the 3rd quarter valued at about $118,000. Finally, Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics in the 2nd quarter valued at about $124,000. Institutional investors own 64.35% of the company’s stock.

Several research firms have commented on SGMO. Wells Fargo & Company restated an “outperform” rating and issued a $30.00 price target (up previously from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Jefferies Group restated a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a report on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, November 15th. Finally, Barclays began coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $17.83.

In other news, Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $73,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.25, for a total value of $228,750.00. The disclosure for this sale can be found here. Insiders sold a total of 84,433 shares of company stock worth $1,309,466 over the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at $16.35 on Friday. Sangamo Therapeutics, Inc. has a 52 week low of $2.85 and a 52 week high of $18.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company’s revenue was up 333.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.27) EPS. sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Sangamo Therapeutics, Inc. (SGMO) Holdings Reduced by Royce & Associates LP” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/16/sangamo-therapeutics-inc-sgmo-holdings-reduced-by-royce-associates-lp.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Stock Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related stocks with our FREE daily email newsletter.